Crinetics Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Crinetics Pharmaceuticals's earnings have been declining at an average annual rate of -33.6%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 28% per year.
Key information
-33.6%
Earnings growth rate
-12.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 28.0% |
| Return on equity | -33.4% |
| Net Margin | -26,747.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely
Oct 02
Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech
Aug 12Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation
Jun 01Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data
May 23Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
Feb 29Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Nov 28Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?
Aug 08Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Dec 31Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
Sep 14Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M
Aug 12We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate
Jun 15Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point
Jun 13Revenue & Expenses Breakdown
How Crinetics Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1 | -278 | 89 | 169 |
| 30 Jun 24 | 1 | -259 | 78 | 169 |
| 31 Mar 24 | 2 | -235 | 67 | 169 |
| 31 Dec 23 | 4 | -215 | 58 | 169 |
| 30 Sep 23 | 5 | -199 | 52 | 130 |
| 30 Jun 23 | 5 | -184 | 49 | 130 |
| 31 Mar 23 | 4 | -175 | 46 | 130 |
| 31 Dec 22 | 5 | -164 | 42 | 130 |
| 30 Sep 22 | 5 | -150 | 38 | 0 |
| 30 Jun 22 | 5 | -136 | 33 | 0 |
| 31 Mar 22 | 4 | -119 | 28 | 0 |
| 31 Dec 21 | 1 | -108 | 25 | 84 |
| 30 Sep 21 | 0 | -98 | 22 | 0 |
| 30 Jun 21 | 0 | -89 | 21 | 0 |
| 31 Mar 21 | 0 | -79 | 19 | 0 |
| 31 Dec 20 | 0 | -74 | 18 | 0 |
| 30 Sep 20 | 0 | -67 | 16 | 0 |
| 30 Jun 20 | 1 | -63 | 16 | 0 |
| 31 Mar 20 | 1 | -59 | 14 | 0 |
| 31 Dec 19 | 1 | -50 | 14 | 0 |
| 30 Sep 19 | 2 | -44 | 13 | 0 |
| 30 Jun 19 | 2 | -38 | 11 | 0 |
| 31 Mar 19 | 2 | -31 | 9 | 0 |
| 31 Dec 18 | 2 | -27 | 7 | 0 |
| 30 Sep 18 | 2 | -21 | 5 | 0 |
| 30 Jun 18 | 2 | -16 | 3 | 0 |
| 31 Mar 18 | 2 | -12 | 3 | 0 |
| 31 Dec 17 | 2 | -9 | 2 | 0 |
| 31 Dec 16 | 1 | -6 | 2 | 0 |
Quality Earnings: CRNX is currently unprofitable.
Growing Profit Margin: CRNX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CRNX is unprofitable, and losses have increased over the past 5 years at a rate of 33.6% per year.
Accelerating Growth: Unable to compare CRNX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: CRNX has a negative Return on Equity (-33.36%), as it is currently unprofitable.